Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Operating Margin (2016 - 2025)

Historic Operating Margin for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to 20.27%.

  • Amicus Therapeutics' Operating Margin rose 49700.0% to 20.27% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.48%, marking a year-over-year increase of 44200.0%. This contributed to the annual value of 4.71% for FY2024, which is 240400.0% up from last year.
  • Amicus Therapeutics' Operating Margin amounted to 20.27% in Q3 2025, which was up 49700.0% from 6.12% recorded in Q2 2025.
  • In the past 5 years, Amicus Therapeutics' Operating Margin registered a high of 20.27% during Q3 2025, and its lowest value of 95.71% during Q1 2022.
  • Its 5-year average for Operating Margin is 31.27%, with a median of 25.11% in 2024.
  • As far as peak fluctuations go, Amicus Therapeutics' Operating Margin crashed by -249200bps in 2022, and later soared by 551200bps in 2023.
  • Quarter analysis of 5 years shows Amicus Therapeutics' Operating Margin stood at 87.82% in 2021, then soared by 45bps to 48.05% in 2022, then skyrocketed by 93bps to 3.21% in 2023, then skyrocketed by 433bps to 10.67% in 2024, then skyrocketed by 90bps to 20.27% in 2025.
  • Its Operating Margin was 20.27% in Q3 2025, compared to 6.12% in Q2 2025 and 6.35% in Q1 2025.